Company news

Immunome, Inc. news in 2024

Immunome, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

November 26, 2024

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024

Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

November 4, 2024

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

October 28, 2024

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

October 17, 2024

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

October 7, 2024

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

September 12, 2024

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

August 28, 2024

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

August 11, 2024

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

July 24, 2024

Immunome Appoints Phil Tsai as Chief Technical Officer

June 26, 2024

Immunome Announces Completion of Purchase of Assets from Atreca

May 19, 2024

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 16, 2024

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

Immunome to Present at 2024 Bank of America Healthcare Conference

May 7, 2024

Immunome Appoints Kinney Horn as Chief Business Officer

May 1, 2024

Immunome Appoints Sandra M. Swain to Board of Directors

April 24, 2024

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

April 4, 2024

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

March 27, 2024

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

March 25, 2024

Immunome to Participate in the Leerink Partners Global Biopharma Conference

March 6, 2024

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

February 29, 2024

Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

February 19, 2024

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

February 19, 2024

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 15, 2024

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

February 5, 2024

Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 4, 2024

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

January 7, 2024

Immunome Appoints Phil Roberts as Chief Technical Officer

January 3, 2024

Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Immunome Appoints Carol A. Schafer to Board of Directors

January 1, 2024

Decks in 2024